1. Home
  2. VLY vs COGT Comparison

VLY vs COGT Comparison

Compare VLY & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp

VLY

Valley National Bancorp

HOLD

Current Price

$11.75

Market Cap

7.6B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$34.04

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLY
COGT
Founded
1927
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
6.0B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
VLY
COGT
Price
$11.75
$34.04
Analyst Decision
Strong Buy
Buy
Analyst Count
13
14
Target Price
$13.92
$34.77
AVG Volume (30 Days)
6.7M
1.6M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
3.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,871,000.00
Revenue This Year
$23.47
N/A
Revenue Next Year
$8.43
$1,180.55
P/E Ratio
$13.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.48
$3.72
52 Week High
$13.87
$43.73

Technical Indicators

Market Signals
Indicator
VLY
COGT
Relative Strength Index (RSI) 35.33 34.08
Support Level $11.57 $32.93
Resistance Level $12.31 $41.02
Average True Range (ATR) 0.37 1.81
MACD -0.15 -0.43
Stochastic Oscillator 7.73 6.42

Price Performance

Historical Comparison
VLY
COGT

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: